search
Back to results

Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use

Primary Purpose

Tobacco Use Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Usual Care Group
Reduction Group
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Nicotine Dependence, Tobacco Dependence

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: No interest in stopping ST use within 90 days of study entry Daily use of ST in the 6 months prior to study entry Exclusion Criteria: Current use of tobacco or nicotine products, other than ST Current unstable medical and mental health conditions Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use Pregnant or breastfeeding

Sites / Locations

  • Univerisity of Minnesota

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Usual Care Group

Reduction Group

Arm Description

Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.

Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.

Outcomes

Primary Outcome Measures

Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence)
No tobacco use 7 days prior to Week 12 verified by biomarkers (urine, cotinine and CO)
Percent Prolonged Abstinence From Tobacco at Week 12
Continuous tobacco cessation from quit date through Week 12 verified by biomarkers (urine, cotinine and CO)
Percent Abstinent From Tobacco at Week 26 (7 Day Point Prevalence)
Abstinence from tobacco 7 days prior to Week 26 (Assessed at 26 weeks for Usual Care and 20 weeks for Reduction Group post-quit date)
Percent Prolonged Abstinence From Tobacco at Week 26
Continuous Abstinence from quit date through Week 26 (Assessed at Week 26 for Usual Care and Week 20 for Reduction Group, Reduction Group's quit date is 6 weeks later than Usual Care).
Percent Abstinent From Tobacco at Week 32 (7 Day Point Prevalence)
Abstinence from tobacco 7 days prior to Week 26 (Assessed at Week 32 for Usual Care and Week 26 for Reduction Group. Reduction Group's quit date is 6 weeks later than Usual Care).
Percent Prolonged Abstinence From Tobacco at Week 32
Continuous Abstinence from quit date through Week 32 (Assessed at Week 32 for Usual Care and Week 26 for Reduction Group, Reduction Group's quit date is 6 weeks later than Usual Care).

Secondary Outcome Measures

Full Information

First Posted
September 16, 2005
Last Updated
September 13, 2017
Sponsor
University of Minnesota
search

1. Study Identification

Unique Protocol Identification Number
NCT00218296
Brief Title
Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Official Title
Treatment of Smokeless Tobacco Users
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
January 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has health risks associated with its use. While treatment programs that focus on stopping tobacco use may be effective, past research has shown that interventions that specifically focus on reducing tobacco use may be equally effective and may motivate individuals to eventually quit using tobacco. This study will compare the effectiveness of a ST reduction treatment program versus a usual tobacco cessation treatment program (immediate cessation) for reducing tobacco use in ST users.
Detailed Description
Individuals who use ST are at increased risk for cancer or dying from cardiovascular disease. Other long-term effects include tooth abrasion, gum recession, and loss of bone in the jaw. Many individuals who use ST recognize the health risks associated with ST, but either do not want to quit or feel that it is impossible to quit. For these individuals, tobacco reduction may be an important transitional goal, either prior to quitting or as a treatment endpoint. By participating in a tobacco reduction program, these individuals may be motivated to eventually stop using tobacco altogether. The purpose of this study is to compare a ST reduction treatment program versus a standard tobacco cessation treatment program (immediate cessation) for reducing tobacco use in ST users. This study will enroll regular users of ST. Participants will be randomly assigned to either a tobacco reduction program or to usual care, a standard tobacco cessation program during the first telephone contact. At the first clinic visit, participants assigned to the tobacco Reduction Group will replace their usual brand of ST with one of two options: an ST brand with less nicotine or nicotine lozenge. Participants will be encouraged to reduce their nicotine intake by at least 50% the first two weeks and encouraged to further reduce their nicotine intake in the following 4 weeks. Participants assigned to the Usual Care Group will be advised to quit and will be asked to set a quit date within two weeks. Telephone counseling, ideas on methods for sustaining cessation, and a self-help manual will also be provided along with a 2 week supply of nicotine patches. Study visits will occur at 2, 4, 8, 12, 26, and 32 (for reduction group) weeks. Outcome assessments will include vital signs, physiological measures related to tobacco use, levels of nicotine reduction, tobacco use status, and measures of motivation and self-efficacy to quit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
Nicotine Dependence, Tobacco Dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
332 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Care Group
Arm Type
Active Comparator
Arm Description
Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
Arm Title
Reduction Group
Arm Type
Experimental
Arm Description
Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
Intervention Type
Drug
Intervention Name(s)
Usual Care Group
Other Intervention Name(s)
21 mg Nicotine Patch, Nicoderm
Intervention Description
Nicotine replacement therapy
Intervention Type
Other
Intervention Name(s)
Reduction Group
Other Intervention Name(s)
Commit Nicotine Lozenge or, Reduced nicotine smokeless tobacco products (Skoal, Skoal Bandits)
Intervention Description
Subject selects preferred method for reduction.
Primary Outcome Measure Information:
Title
Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence)
Description
No tobacco use 7 days prior to Week 12 verified by biomarkers (urine, cotinine and CO)
Time Frame
12 weeks
Title
Percent Prolonged Abstinence From Tobacco at Week 12
Description
Continuous tobacco cessation from quit date through Week 12 verified by biomarkers (urine, cotinine and CO)
Time Frame
12 weeks
Title
Percent Abstinent From Tobacco at Week 26 (7 Day Point Prevalence)
Description
Abstinence from tobacco 7 days prior to Week 26 (Assessed at 26 weeks for Usual Care and 20 weeks for Reduction Group post-quit date)
Time Frame
26 week
Title
Percent Prolonged Abstinence From Tobacco at Week 26
Description
Continuous Abstinence from quit date through Week 26 (Assessed at Week 26 for Usual Care and Week 20 for Reduction Group, Reduction Group's quit date is 6 weeks later than Usual Care).
Time Frame
26 weeks
Title
Percent Abstinent From Tobacco at Week 32 (7 Day Point Prevalence)
Description
Abstinence from tobacco 7 days prior to Week 26 (Assessed at Week 32 for Usual Care and Week 26 for Reduction Group. Reduction Group's quit date is 6 weeks later than Usual Care).
Time Frame
32 Weeks
Title
Percent Prolonged Abstinence From Tobacco at Week 32
Description
Continuous Abstinence from quit date through Week 32 (Assessed at Week 32 for Usual Care and Week 26 for Reduction Group, Reduction Group's quit date is 6 weeks later than Usual Care).
Time Frame
32 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: No interest in stopping ST use within 90 days of study entry Daily use of ST in the 6 months prior to study entry Exclusion Criteria: Current use of tobacco or nicotine products, other than ST Current unstable medical and mental health conditions Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use Pregnant or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dorothy Hatsukami, PhD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
Univerisity of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55414
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22218402
Citation
Schiller KR, Luo X, Anderson AJ, Jensen JA, Allen SS, Hatsukami DK. Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. Nicotine Tob Res. 2012 Aug;14(8):902-9. doi: 10.1093/ntr/ntr302. Epub 2012 Jan 4.
Results Reference
result
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/22218402
Description
Schiller KR, Luo X, Anderson AJ, Jensen JA, Allen SS, Hatsukami DK. Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. Nicotine Tob Res 2012.

Learn more about this trial

Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use

We'll reach out to this number within 24 hrs